Sixth Wave Partners with York University and CTRI to Advance Virus Detection Technology
Halifax, Nova Scotia--(Newsfile Corp. - June 15, 2020) - Sixth Wave Innovations Inc. (CSE: SIXW) (OTC: ATURF) (FSE: AHUH) ("Sixth Wave" or the "Company") is pleased to announce that it has partnered with York University ("York") and the Centre Technologique des Residus Industriels ("CTRI"), (the "Partnership"), for the development of its AMIPs virus detection technology through the submission of a grant application to Natural Sciences and Engineering Research Council of Canada ("NSERC").
The grant application is titled: Point-of-need Microfluidic Biosensor for Detecting Airborne Viruses using Molecularly Imprinted Polymers: Towards COVID-19 Virus Monitoring (the "Proposal") and is for the development of a portable and low-cost technology for rapid on-site air sampling and detection of aerosol and droplet-encapsulated viruses in indoor and outdoor environments.
Pursuant to the terms of the Proposal, Sixth Wave will contribute its proposed AMIPs detection technology to be incorporated into the design of one of the first field-deployable air monitoring systems used for the detection of viruses such as SARS-CoV-2 (the "Air Monitoring System").
Upon design completion, the Partnership plans to develop a prototype that will be tested and used in an array of settings including but not limited to the pubic sector, private industry, hospitals, long-term healthcare facilities, and various forms of public transportation.
If successfully developed, the Air Monitoring System would be able to provide proactive virus detection capabilities to help maintain confidence in public settings and in the reopening of previously contaminated locations. The Air Monitoring System could be used to provide surveillance and mapping of virus hot spots to further assist in the prevention of additional virus infection. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
"Sixth Wave's AMIPs detection technology, which is currently under development, provides a perfect platform to build the products envisioned in the Proposal," noted Dr. Sara Magdouli of CTRI. Dr. Magdouli continued, "We approached Sixth Wave to participate because of their demonstrated success with developing molecular imprinted polymer solutions in the past." Dr. Magdouli is a Laboratory Coordinator with CTRI and holds a master's degree in Biotechnology for Sustainable Development from the University of Aix-Marseille in France and a master's degree in Environmental Microbiology from the National Institute of Applied Sciences and Technology in Tunis.
"Sixth Wave is honored to have been approached and selected by York University and CTRI for this high priority collaboration," stated Dr. Jonathan Gluckman, President and CEO of Sixth Wave. "In another project with CTRI, Sixth Wave is contributing it's IXOS® technology for the development of green mining alternatives and this current Partnership continues to develop and strengthen the relationship between CTRI and Sixth Wave."
About Sixth Wave
Sixth Wave is a development stage nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Accelerated Molecularly Imprinted Polymers (AMIPs). The Company is in the process of commercializing its AffinityTM cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry.
Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.
For more information about Sixth Wave, please visit our web site at: www.sixthwave.com
ON BEHALF OF THE BOARD OF DIRECTORS
Jonathan Gluckman, Ph.D., President & CEO
For information, please contact the Company:
Phone: (801) 582-0559
This press release includes certain statements that may be deemed "forward-looking statements" including statements regarding the planned features, capacity and performance of the AMIPs technology and the planned Air Monitoring System. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs technology are subject the risk that the AMIPs technology may not prove to be successful in detecting virus targets effectively or at all, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57884